Please login to the form below

Not currently logged in
Email:
Password:

Almirall/ Nycomed COPD co-branding deal

Almirall and Nycomed have entered into a co-branding agreement for the commercialisation of roflumilast, a once-daily tablet for patients with chronic obstructive pulmonary disease, in Spain

Almirall and Nycomed have entered into a co-branding agreement for the commercialisation of roflumilast, the once-daily tablet for patients with chronic obstructive pulmonary disease (COPD), in Spain.

Roflumilast is an orally administered phosphodiesterase 4 (PDE4) enzyme inhibitor, and the first oral anti-inflammatory treatment for COPD.

Nycomed will receive an undisclosed upfront fee from Almirall, who will be exclusively promoting a second brand of roflumilast in Spain.

Luciano Conde, Almirall's chief operating officer, said: "This product, an entirely new class of treatment, has a strong strategic fit in our business and is fully complementary with other bronchodilator treatments in COPD such as our R&D product aclidinium bromide which is expected to be filed this year.

"We expect roflumilast to generate sales as of this year and could become one of Almirall's key products in the mid-term," he added.

5th May 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Numbers, navigation, and narratives: digital storytelling in medical communications
Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
Is this common data mistake killing your digital patient recruitment?
Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...
Stick or Twist? Healthcare brands in a (post) COVID-19 world
...